Unicycive
  • Company
  • Therapeutic Focus
  • Pipeline
    • UNI-494
    • Renazorb
  • Investors
  • Contact

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Jan 10, 2022 7:00am EST

Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Nov 29, 2021 7:00am EST

Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway

Nov 11, 2021 9:14am EST

Unicycive Therapeutics Announces Third Quarter 2021 Financial Results

Oct 26, 2021 7:30am EDT

Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

Sep 15, 2021 6:17am EDT

Unicycive Therapeutics to be Added to Russell Microcap® Index

Sep 07, 2021 6:00am EDT

Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16, 2021 6:00am EDT

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

Jul 13, 2021 8:30am EDT

Unicycive Therapeutics Announces Pricing of Initial Public Offering

Dec 14, 2020 9:30am EST

Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease

Jun 16, 2020 9:38am EDT

Keith Ward, Ph.D. Joins as the Chief Development Officer of Unicycive

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Legal Notices and Terms of Use
Privacy Policy
Ad and Cookie Policy
Contact Us >

Copyright © 2023 Unicycive

  • Twitter
  • LinkedIn